About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.
Subscribe to this blog's feed

Contact the Docs

Recent Posts

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Court Report | Main | PLI's John White Discusses Tafas/GSK v. Dudas »

February 11, 2008

Human Genome Sciences and Xencor Enter Antibody Collaboration

    By Christopher P. Singer --

Hgs On February 7, 2008, Human Genome Sciences, Inc. (HGS) and Xencor, Inc. announced that the two companies will enter a collaboration agreement relating to Xencor's proprietary XmAb™ humanization and optimization technologies.  Xencor's technology will be applied to several new monoclonal antibody drug candidates developed against antigens discovered by HGS.

Xencor_2 Under the agreement, Xencor will receive an upfront payment and is eligible for additional payments for development and commercial milestones, as well as royalty payments on any commercialized products arising from the agreement.  All preclinical and clinical development, manufacturing and commercialization will be handled by HGS.

According to Xencor, its XmAb™ engineered Fc domains are designed to improve one or more important effector functions of an antibody candidate, such as enhanced antibody-mediated tumor cell killing, extended half-life, and selective regulation of immune cells.  Xenxor's XmAb™ Fv technology generates high-quality human sequence diversity in antibody variable domains in order to improve affinity, stability, and production yield.

Posted at 10:03 PM in Licensing |

Comments

The comments to this entry are closed.

January 2025

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

Categories

Archives

More...